135 related articles for article (PubMed ID: 7819617)
1. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
[TBL] [Abstract][Full Text] [Related]
2. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
3. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
[TBL] [Abstract][Full Text] [Related]
4. Prolonged and repeated courses of OKT3 after liver transplantation.
Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
[No Abstract] [Full Text] [Related]
5. OKT3 resistant rejection in liver transplant patients.
Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
[No Abstract] [Full Text] [Related]
6. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
7. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction.
Sheiner PA; Guarrera JV; Grunstein E; Emre S; Guy SR; Schwartz ME; Miller CM; Boros P
Transplantation; 1997 Oct; 64(8):1214-6. PubMed ID: 9355846
[TBL] [Abstract][Full Text] [Related]
8. The effect of rabbit antithymocyte serum (RATS) and OKT3 on peripheral blood mononuclear cell subsets following renal transplantation.
Zaltzman JS; Cole EH; Freedman J
Clin Transplant; 1994 Dec; 8(6):516-22. PubMed ID: 7865912
[TBL] [Abstract][Full Text] [Related]
9. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
10. CD3 antigen modulation in T-lymphocytes during OKT3 treatment.
Magnussen K; Klug B; Møller B
Transplant Proc; 1994 Jun; 26(3):1731. PubMed ID: 8030108
[No Abstract] [Full Text] [Related]
11. Presence of different T and B-peripheral blood lymphocyte subsets in liver transplantation after cyclosporine or OKT3 immunosuppressive treatment.
Minguela A; Alvarez-López MR; Sánchez-Bueno F; Torío A; Muro M; Robles R; Pons JA; Parrilla P; García-Alonso AM
Transplant Proc; 1995 Aug; 27(4):2317-8. PubMed ID: 7652825
[No Abstract] [Full Text] [Related]
12. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
13. The expression patterns of CD44 and CD45RB on peripheral blood T lymphocytes in the rejection of allogeneic murine skin transplantation.
Yang J; Ahn C; Jung HK; Kim EK; Kim JY; Kim YS; Han JS; Kim S; Lee JS
Transpl Immunol; 2003; 11(2):197-206. PubMed ID: 12799204
[TBL] [Abstract][Full Text] [Related]
14. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
15. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
[TBL] [Abstract][Full Text] [Related]
16. Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation.
Shaddy RE; Bullock EA; Morwessel NJ; Hannon DW; Renlund DG; Karwande SV; McGough EC; Hawkins JA
J Heart Lung Transplant; 1993; 12(3):434-9. PubMed ID: 8329414
[TBL] [Abstract][Full Text] [Related]
17. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
Carrier M; Jenicek M; Pelletier LC
Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
[No Abstract] [Full Text] [Related]
18. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response against OKT3.
Chatenoud L
Transplant Proc; 1993 Apr; 25(2 Suppl 1):68-73. PubMed ID: 8465430
[No Abstract] [Full Text] [Related]
20. [Immunologic surveillance of liver transplant patients using monoclonal antibodies against lymphocyte subpopulations].
Gugenheim J; Canon C; Samuel D; Saliba F; Debotte G; Misset JL; Mathe G; Bismuth H
Nephrologie; 1987; 8(3):99-101. PubMed ID: 3116444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
